Gene therapy

Exclusive Megan Molteni

STAT Plus: The Afghan father aided U.S. soldiers. Now Texas Medicaid won’t pay for his son’s gene therapy

Special Report Brittany Trang

STAT Plus: Gene therapy offered this 7-year-old freedom. The price: a grueling year

Biotech Jason Mast

STAT Plus: Could sickle cell someday be treated not with CRISPR, but with a pill?

Health Jonathan Wosen

STAT Plus: Bone marrow transplant advance could widen use of this less buzzy cure for sickle cell disease

First Opinion Robert Brodsky

New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists

Biotech Brittany Trang

STAT Plus: Tough road ahead for Bluebird Bio despite FDA approval for sickle cell therapy

First Opinion Jennifer Fields

After living with sickle cell disease for 39 years, I’m both excited and skeptical about the newly approved gene therapies

Special Report Megan Molteni

New gene therapies confront many sickle cell patients with an impossible choice: a cure or fertility

Politics Sarah Owermohle

STAT Plus: Official: FDA needs staff influx to meet gene therapy needs

Biotech Jason Mast

STAT Plus: How sickle cell became the first disease treated by CRISPR

First Opinion Richard Burr

STAT Plus: The FDA is at a crossroads on cell and gene therapies

The Readout Damian Garde

STAT Plus: Gene editing has had a big week in the spotlight. Here’s what’s going on

First Opinion Vivian G. Cheung

STAT Plus: How the government can help lower the price — not just the cost — of cutting-edge gene therapies

Biotech Jonathan Wosen

STAT Plus: Cell and gene therapy CEOs share survival strategies amid biotech slump

Biotech Jason Mast

STAT Plus: Taysha Gene Therapies’ plan to tackle rare diseases is crumbling

Biotech Jason Mast

STAT Plus: Gene therapy death was caused by an unknown risk of the virus used, study suggests

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.

In the Lab Jason Mast

They carry a gene for ALS but aren’t sick. What does medical research owe them?

Hospitals Tara Bannow

STAT Plus: Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue

Biotech Jason Mast

STAT Plus: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Racing for gene therapy, a pioneering approval, & startups in the lurch

Biotech Jason Mast

With an age cutoff for a new gene therapy, families and doctors scramble to treat kids before their 6th birthday

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Biotech layoffs, eye drug drama, & gene therapy milestones

Biotech Jason Mast

STAT Plus: Gene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution

Biotech Jason Mast

STAT Plus: AstraZeneca buys early-stage gene therapies from Pfizer in boon for struggling field

First Opinion Podcast Torie Bosch

One Duchenne patient’s bittersweet hope for new treatment

Biotech Adam Feuerstein

STAT Plus: BioMarin wins approval for gene therapy to treat hemophilia A

Biotech Jason Mast

STAT Plus: After promising early data, gene therapy trial for Huntington’s takes puzzling turn

Biotech Jason Mast

STAT Plus: After gene therapy deaths, Astellas brings in potentially safer treatment for muscle disorder